Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
01 June 2004Website:
http://www.angiodynamics.comNext earnings report:
03 January 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 00:12:09 GMTDividend
Analysts recommendations
Institutional Ownership
ANGO Latest News
ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.
AngioDynamics announces the receipt of CPT Category I code for IRE technology.
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.
ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors.
Investors didn't like the medical technology company's fiscal 2025 Q1 update.
AngioDynamics (ANGO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter Highlights Quarter Ended August 31, 2024 Pro Forma* YoY Growth Net Sales $67.5 million.
AngioDynamics, Inc. ANGO will release earnings results for its first quarter, before the opening bell on Thursday, Oct. 3.
MRX, ANGO, OPRA, ATAT and PAM have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2024.
What type of business is AngioDynamics?
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
What sector is AngioDynamics in?
AngioDynamics is in the Healthcare sector
What industry is AngioDynamics in?
AngioDynamics is in the Medical Instruments & Supplies industry
What country is AngioDynamics from?
AngioDynamics is headquartered in United States
When did AngioDynamics go public?
AngioDynamics initial public offering (IPO) was on 01 June 2004
What is AngioDynamics website?
https://www.angiodynamics.com
Is AngioDynamics in the S&P 500?
No, AngioDynamics is not included in the S&P 500 index
Is AngioDynamics in the NASDAQ 100?
No, AngioDynamics is not included in the NASDAQ 100 index
Is AngioDynamics in the Dow Jones?
No, AngioDynamics is not included in the Dow Jones index
When was AngioDynamics the previous earnings report?
No data
When does AngioDynamics earnings report?
The next expected earnings date for AngioDynamics is 03 January 2025